2N Pharma

A sincere thank you to Ambassador Alan M. Leventhal and U.S. Embassy Copenhagen for hosting a reception for members of the US and Danish life science community (and for once again inviting our CEO Preben Bruun-Nyzell). 2N Pharma benefits very concretely from a strong relationship with the United States as part of our work to develop new drugs to treat ALS is funded by the US Department of Defense through the Congressionally Directed Medical Research Programs. #endALS #als

A year goes by really fast! Since 2N Pharma won the Nordic Mentor Network For Entrepreneurship - NOME Startup Competition last year, we have had the benefit of mentoring by very experienced industry experts, participated in the NOME US Program with inspirational visits to Boston and New York City, and joined fellow NOME companies at investor events. We can highly recommend NOME for biotech entrepreneurs! We would like to thank our mentors Hilde H. Steineger, Claus Bo Svendsen MD PhD MBA, Torben Skarsfeldt, D.Sc. and NOME's Peter Birk for your counsel over the last year. Unfortunately, the desperate unmet medical need for effective ALS medicine has not improved. 2N Pharma is developing a new drug based on our pioneering neurometabolic approach with excellent pre-clinical efficacy data and compelling genetic support. #endALS #ALS #neurodegeneration

If you missed our CEO Preben Bruun-Nyzell's presentation at the Redeye Neurology 2024 event, here is an opportunity to view the recording. If you spend 20 minutes watching this, you will get an introduction to 2N Pharma's work to develop new drugs to treat ALS and some insights into the commercial opportunity related to this. https://lnkd.in/dwKMX7zd

Join 2N Pharma on 23 October 2024 for the free Redeye Neurology Event, where we'll be presenting our novel approach of targeting neurometabolic imbalances to treat ALS and other brain diseases. Did you know that the average age of people diagnosed with ALS is 55 years old and half die within 2 years? The only drug available in Europe is almost 30 years old and has very limited effect. There is a desperate need for new treatment options, and with that comes an incredible business case. Join the event for free (2N Pharma's presentation is around 10:40 CET): https://lnkd.in/e54ywhqB #neurodegeneration #ALS

Join 2N Pharma on 23 October 2024 for the free Redeye Neurology Event, where we'll be presenting our novel approach of targeting neurometabolic imbalances to treat ALS and other brain diseases. Did you know that the average age of people diagnosed with ALS is 55 years old and half die within 2 years? The only drug available in Europe is almost 30 years old and has very limited effect. There is a desperate need for new treatment options, and with that comes an incredible business case. Join the event for free (2N Pharma's presentation is around 10:40 CET): https://lnkd.in/e54ywhqB #neurodegeneration #ALS

🚀 2N Pharma is on the road 🌍 As the conference season kicks off, we are excited to announce our participation in several key events over the next couple of months: LSX Nordic Congress 📆 Oct 8 - Oct 9, 2024 📍Copenhagen, Denmark 17th Drug Discover Strategic Summit  📆 Oct 23 - Oct 24, 2024 📍Munich, Germany Redeye AB´s 7th Annual Event on Drug Development in Neurology and Brain Diseases 📆 Oct 23, 2024 📍Stockholm, Sweden BIO-Europe EBD Group 📆 Nov 4 - Nov 6, 2024 📍Stockholm, Sweden These events offer incredible opportunities to connect, share insights, and explore the latest trends shaping the biotech and pharmaceutical industries. We are looking forward to engaging in discussions and meeting with partners, and investors. Let’s connect! If you are attending any of these conferences and would like to schedule a one-on-one meeting, feel free to reach out. We cannot wait to explore new possibilities together! #Biotech #Pharma #Innovation #Networking #2NPharma #ConferenceSeason #ALS #neuroscience #ResearchofALS #EndALS

Will we see you at LSX Nordic Congress? 🌟 Next week, 2N Pharma’s CEO, Preben Bruun-Nyzell, will be attending the event. He is excited to connect with potential partners, investors, and industry experts. See you there! #LSXNORDIC #biotech #pharma #networking #alsresearch #neuroscience

Will we see you at LSX Nordic Congress? 🌟 Next week, 2N Pharma’s Head of Biology, Steinunn Sara Helgudóttir, will be attending the event. She is excited to connect with potential partners, investors, and industry experts. See you there! #LSXNORDIC #biotech #pharma #networking #alsresearch #neuroscience

What an inspiring ALS conference hosted by Muskelsvindfonden this weekend 🙌 A heartfelt thank you to the organizers, presenters, ALS patients, and their families for sharing such invaluable knowledge and experiences about #ALS. After a few exciting days, the 2N Pharma team is more motivated than ever to continue our work on developing biomarkers for earlier ALS diagnosis and advancing #Mitometin, with the hope of improving the quality of life for ALS patients. We look forward to contributing even more to this critical cause 💙 #ALSResearch #2NPharma #Mitometin #earlydiagnosis #neurology #ALS

Join us at #NLSDays today🩵 The 2N Pharma team is thrilled to be at #NLSDays, engaging with the nordic community of biotech and life science innovators 🤩 We are eager to connect with professionals, exchange valuable insights, and explore collaborative opportunities that push the boundaries of neuroscience 🧠💊 Let’s drive the future of neuroscience together! #NLSDays #Biotech #LifeSciences #Neuroscience #Innovation #ALS #Sweden #Collaboration